Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05686733
Other study ID # TP0068
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 26, 2022
Est. completion date February 17, 2024

Study information

Verified date March 2024
Source Galaxy Therapeutics INC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To establish the preliminary safety and effectiveness of the SEAL™ Endovascular Aneurysm Lattice System for the treatment of saccular intracranial aneurysms. The data from this study will be used to support: 1. EU CE Mark labelling 2. US FDA Investigational Device Exemption (IDE) approval support of PMA approval.


Description:

First In Human (FIH), prospective, single-arm, multicenter, interventional study. Patients presenting with evidence of a single unruptured or ruptured aneurysm requiring treatment will be enrolled into the study and treated using the SEAL™ System. Immediate post-procedure angiographic findings, clinical presentation, safety, and imaging follow-up for each subject will be collected at 24 hours, 3 (MRA), 6, 12 and 24-months post-procedure.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date February 17, 2024
Est. primary completion date February 17, 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria: 1. 20 to 80 years of age at the time of screening 2. Evidence of a single unruptured aneurysm requiring treatment. If there is evidence of an additional aneurysm requiring treatment, the secondary aneurysm must also be treatable using a SEAL™ System Device, either during a single procedure or consecutive procedures. In these instances, no additional implanted devices are permissible except for as medically required for patient safety. 1. Ruptured aneurysms may be included according the following criteria: The subject is neurologically stable with a Hunt and Hess scale of 3 or less at the time of treatment 2. Modified Disability Scale (mRS) of =2 prior to presentation or rupture 3. The index intracranial aneurysm (IA) to be treated must include the following features: 1. Aneurysm features suitable for endovascular treatment with an intrasaccular device per the treating interventionist. 2. Saccular morphology 3. Located at a bifurcation, terminus, or sidewall in the anterior or posterior circulation 4. 3mm-25mm in dome diameter 5. Narrow or wide-neck aneurysm with neck size = 4mm or Dome-to-Neck (DN) ratio < 2 4. Aneurysm treatment does not require the preplanned use of any additional implanted devices 5. Subject is able to maintain compliance with all aspects of screening, evaluation, treatment, and post-procedure follow-up schedule 6. Baseline mRS of 0-1 for unruptured cases 7. Ability to obtain written informed consent from subject prior to the initiation of any study procedures 8. Subject has been approved for inclusion by Galaxy Therapeutics INC. clinical affairs team. Exclusion Criteria: 1. Aneurysm features unsuitable for endovascular treatment with an intrasaccular device such as fusiform, dissecting pseudo aneurysm, or mycotic aneurysm. 2. Aneurysms smaller than 3mm and larger than 25mm in dome diameter. 3. Inability to access target aneurysm with microcatheter due to intracranial atherosclerosis, vessel tortuosity or poor aneurysm angle take-off. 4. Presence of vascular disease or other vascular abnormality that could prohibit access to index aneurysm such carotid stenosis or diminished caliber of the target artery. 5. Proximal vessel tortuosity or morphology that could prohibit access to target aneurysm 6. Clinical, angiographic, or CT evidence of CNS arterial vasculitis, moyamoya disease, intracranial tumor (except small meningioma), or any other intracranial vascular malformations 7. Patients with high risk for recurrent ischemic stroke due to previous history of intracranial ischemic stroke symptoms such as transient ischemic attacks (TIAs), minor, or major strokes within the past 60 days 8. Patients with hemodynamic or medical compromise due to medical comorbidities such as severe unstable congestive heart failure (ejection fraction <30%) or severe COPD requiring home oxygen. 9. Modified Rankin Scale (mRS) score of = 2 prior to presentation or acute rupture (as applicable) 10. SAH from non-index aneurysm or any other intracranial hemorrhage within the past 60 days 11. Target aneurysm has been previously treated and contains devices, implants, or coils that could interfere with correct SEAL™ device placement. 12. Subject is pregnant or a lactating female (For females of child-bearing potential, a positive pregnancy test within 7 days of the day of procedure or refusal to use a medically accepted method of birth control for the duration of the study. 13. Currently on anticoagulation therapy or has a known blood dyscrasia, coagulopathy, or hemoglobinopathy 14. Hypersensitivity that cannot be medically controlled to any component of the SEAL™ System, procedural materials, or medications commonly used during the procedure 15. Currently enrolled in another investigational study or post-market study that could affect the safety and efficacy of aneurysm treatment or interfere with the study follow- up schedule 16. Presence of an acute life-threatening illness requiring treatment 17. Life-expectancy of < 5 years 18. Subject has an uncontrolled co-morbid medical condition, including mental health issues, that would adversely affect participation in the study 19. Subject is a prisoner or member of other vulnerable population

Study Design


Related Conditions & MeSH terms


Intervention

Device:
SEAL Device
Endovascular treatment of target aneurysm using the Saccular Endovascular Aneurysm Lattice (SEAL) device.

Locations

Country Name City State
Colombia Clinicas Las Americas Medellin Antioquia

Sponsors (1)

Lead Sponsor Collaborator
Galaxy Therapeutics INC

Country where clinical trial is conducted

Colombia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Safety Endpoint Subject Safety will be considered a failure upon meeting any of the following primary safety criteria:
Any stroke within 72 hours of the procedure or discharge home (if earlier) that results in an increase of 4 or more points on the National Institute of Health Stroke Scale
Major ipsilateral stroke within 72 hours post-procedure or discharge home (if earlier) to 12-months following treatment
New subarachnoid hemorrhage related to target aneurysm within 72 hours post-procedure or discharge home (if earlier) to 12-months following treatment
Death due to neurologic cause related to aneurysm treated from Procedure to 12-months following treatment
Procedure through 12 Months
Primary Primary Efficacy Endpoint Proportion of subjects with aneurysm occlusion adjudicated by independent core lab based on satisfaction of the following 3 criterion:
WEB-IT Occlusion Scale I and II (WOS) post-implantation, at 6 months, and at 12 months
Raymond Roy Scale I (RRS) post-implantation, at 6 months, and at 12 months
Technical success defined as the proportion of subjects in whom a SEAL™ System was successfully delivered and deployed at the target aneurysm
Procedure through 12 Months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06235619 - Arch Size Study for Anatomical Variations
Completed NCT01178710 - Effect of Simvastatin on Cardiac Function N/A
Not yet recruiting NCT00905931 - Lycopene Following Aneurysmal Subarachnoid Haemorrhage Phase 2
Completed NCT00349908 - A Feasibility Study of the Cordis Neurovascular Self Expanding Stent System in Intracranial Arteries Phase 1
Recruiting NCT03285100 - The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation N/A
Recruiting NCT06189950 - Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms:REBRIDGE N/A
Active, not recruiting NCT04592185 - The Study of the Fenestrated Anaconda Device in the Treatment of Abdominal Aortic Aneurysms
Completed NCT01970605 - Silver Graft All Comers Registry
Completed NCT00282893 - Balloon Prophylaxis of Aneurysmal Vasospasm Phase 2
Active, not recruiting NCT00549380 - Clinical Study of Aneurysm Exclusion Phase 1
Completed NCT04598802 - COvera in BRAnch Registry
Completed NCT04246125 - Patient Skin Dose in Interventional Radiology
Recruiting NCT05829746 - PROSPECTIVE, MULTI-CENTER, OPEN-LABEL, SINGLE-ARM REGISTRATION TRIAL OF THE TUBRIDGE FOR THE TREATMENT OF WIDE-NECKED SMALL AND MEDIUM-SIZED INTRACRANIAL ANEURYSMS N/A
Completed NCT03242343 - VasQ External Support for Arteriovenous Fistula N/A
Recruiting NCT02878967 - Standardized Long Term Follow-up of Patients After Endovascular Embolization of a Brain Aneurysm
Active, not recruiting NCT02345005 - Iliac Branch Excluder ReGistry (IceBERG)
Recruiting NCT02167997 - EffectiveNess and SAfety of Small ANeurysm COiling Trial N/A
Recruiting NCT00549016 - Clinical Study of Aneurysm Exclusion N/A
Completed NCT02848612 - Evaluation of the Amiens University Hospital Neuroradiology Anticoagulation Protocol
Enrolling by invitation NCT04269447 - Prospective Aortic Biobank of POP-STAR